α1‐Adrenoceptors are seven transmembrane domain GPCRs involved in numerous
physiological functions controlled by the endogenous catecholamines, noradrenaline and …

Aims Prostate cancer is the second most frequently malignancy in men worldwide. Most
deaths are caused by metastasis, and tumor cell dissemination involves the interaction with …

Naftopidil (NAF) is a α 1D/1A adrenoceptor selective drug used for the treatment of both
benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS). However, NAF …

In the scope of a research program aimed at developing new drugs for the treatment of
central nervous system diseases, we describe herein the synthesis and pharmacological …

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a complex disease that is
often accompanied by mental health disorders. However, the potential mechanisms …

Benign prostate hyperplasia (BPH) is a common disease in old-age males, accounting for
approximately 77% of morbidity within the age range of 40 to 70 years. It has been shown …

Purpose Benign prostatic hyperplasia (BPH) impacts quality of life in men by causing lower
urinary tract symptoms. α1-Adrenoceptor (α1-AR) blockers improve lower urinary tract …

Although the use of games as an educational strategy is an important current trend, there is
practically no option available for training people on the Drug Discovery and Development …

Benign prostatic hyperplasia (BPH) is an aging-related and progressive disease linked to an
up-regulation of α 1-adrenoceptors. The participation of EGF receptors (EGFR) in the …

This study aimed to estimate the absorption, distribution, metabolism and excretion (ADME)
properties and safety of LDT5, a lead compound for oral treatment of benign prostatic …